• Je něco špatně v tomto záznamu ?

Symptomatic malignant ascites drainage with a patient-controlled vascular catheter: interim analysis of safety and patient-reported outcomes

M. Stukan, M. Jędryka, A. Cokan, J. Klát, MI. Ndukwe, M. Kryszpin, R. Poblocka, E. Timošek, M. Romanová, K. Balcarová, R. Madry, D. Cibula

. 2025 ; 33 (3) : 202. [pub] 20250219

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009851

Malignant ascites (MA) and repeated paracentesis can impair a patient's quality of life (QOL). The aim was to perform an interim analysis of safety and changes in patients' QOL in an ongoing prospective, multicentre (conducted within the Central and Eastern European Gynaecologic Oncology Group (CEEGOG)) trial on symptomatic MA drainage with a patient-controlled central vascular catheter (CVC) inserted into the abdominal cavity. CVC (14-Ga) was inserted into the abdominal cavity of patients with symptomatic MA, and drainage was controlled by patients at home. The rate and quality of complications were classified according to Common Terminology Criteria for Adverse Events Version 5.0. QOL was evaluated before and 10-14 days after/during drainage with standardized QLQ-C15-PAL, SGA, and FACIT-TS-G questionnaires. Wilcoxon and Chi-squared tests were used. Among 113 recruited patients (2015-2022), seven patients experienced complications (6.2%), and there was one patient with a serious adverse event (death on the 9th day after catheter insertion, classified as not related to the intervention). Adverse events included local infection (n = 2) (resolved after oral antibiotics), catheter obstruction (n = 2), catheter self-removal (n = 2) (re-insertion performed), and nausea (n = 1). When comparing the assessment before and after/during drainage, we found the significantly better global QOL (mean 31.8 vs. 47.8, p < 0.001), improvement in physical (52.6 vs. 64.4, p < 0.001) and emotional functioning (50.7 vs. 65.4, p < 0.001); symptoms were significantly less intense: fatigue (66.7 vs. 50.9, p < 0.001), nausea and vomiting (37.8 vs. 21.4, p < 0.001), pain (53.9 vs. 34.1, p < 0.001), dyspnoea (48.5 vs. 22.3, p < 0.001), insomnia (49.1 vs. 34.3, p < 0.001), appetite loss (56.3 vs. 40.3, p < 0.001), and constipation (31.0 vs. 25.2, p = 0.007), and more patients had no pain on eating (71.3% vs. 82.9%, p = 0.04). Most patients (78%) were satisfied, 83% would recommend the procedure to others, and 90% would choose intervention again. The interim analysis provided data on the safety and improvement of patients' QOL after MA drainage via patient-controlled CVC inserted into the abdominal cavity, thus justifying the continuation of recruitment for the main trial without changes in the protocol.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009851
003      
CZ-PrNML
005      
20250429134824.0
007      
ta
008      
250415s2025 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00520-025-09265-4 $2 doi
035    __
$a (PubMed)39969588
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Stukan, Maciej $u Department of Gynecological Oncology, Gdynia Oncology Center, Pomeranian Hospitals, Gdynia, Poland. maciej.stukan@gmail.com $u Surgical Oncology Clinic, Gdansk Medical University, Gdansk, Poland. maciej.stukan@gmail.com
245    10
$a Symptomatic malignant ascites drainage with a patient-controlled vascular catheter: interim analysis of safety and patient-reported outcomes / $c M. Stukan, M. Jędryka, A. Cokan, J. Klát, MI. Ndukwe, M. Kryszpin, R. Poblocka, E. Timošek, M. Romanová, K. Balcarová, R. Madry, D. Cibula
520    9_
$a Malignant ascites (MA) and repeated paracentesis can impair a patient's quality of life (QOL). The aim was to perform an interim analysis of safety and changes in patients' QOL in an ongoing prospective, multicentre (conducted within the Central and Eastern European Gynaecologic Oncology Group (CEEGOG)) trial on symptomatic MA drainage with a patient-controlled central vascular catheter (CVC) inserted into the abdominal cavity. CVC (14-Ga) was inserted into the abdominal cavity of patients with symptomatic MA, and drainage was controlled by patients at home. The rate and quality of complications were classified according to Common Terminology Criteria for Adverse Events Version 5.0. QOL was evaluated before and 10-14 days after/during drainage with standardized QLQ-C15-PAL, SGA, and FACIT-TS-G questionnaires. Wilcoxon and Chi-squared tests were used. Among 113 recruited patients (2015-2022), seven patients experienced complications (6.2%), and there was one patient with a serious adverse event (death on the 9th day after catheter insertion, classified as not related to the intervention). Adverse events included local infection (n = 2) (resolved after oral antibiotics), catheter obstruction (n = 2), catheter self-removal (n = 2) (re-insertion performed), and nausea (n = 1). When comparing the assessment before and after/during drainage, we found the significantly better global QOL (mean 31.8 vs. 47.8, p < 0.001), improvement in physical (52.6 vs. 64.4, p < 0.001) and emotional functioning (50.7 vs. 65.4, p < 0.001); symptoms were significantly less intense: fatigue (66.7 vs. 50.9, p < 0.001), nausea and vomiting (37.8 vs. 21.4, p < 0.001), pain (53.9 vs. 34.1, p < 0.001), dyspnoea (48.5 vs. 22.3, p < 0.001), insomnia (49.1 vs. 34.3, p < 0.001), appetite loss (56.3 vs. 40.3, p < 0.001), and constipation (31.0 vs. 25.2, p = 0.007), and more patients had no pain on eating (71.3% vs. 82.9%, p = 0.04). Most patients (78%) were satisfied, 83% would recommend the procedure to others, and 90% would choose intervention again. The interim analysis provided data on the safety and improvement of patients' QOL after MA drainage via patient-controlled CVC inserted into the abdominal cavity, thus justifying the continuation of recruitment for the main trial without changes in the protocol.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a ascites $x etiologie $x terapie $7 D001201
650    12
$a kvalita života $7 D011788
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a senioři $7 D000368
650    12
$a drenáž $x metody $x škodlivé účinky $7 D004322
650    _2
$a mužské pohlaví $7 D008297
650    12
$a hodnocení výsledků péče pacientem $7 D000071066
650    _2
$a nádory $x komplikace $x terapie $7 D009369
650    _2
$a dospělí $7 D000328
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a průzkumy a dotazníky $7 D011795
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Jędryka, Marcin $u Wroclaw Medical University, Wroclaw, Poland $u Lower Silesian Oncology, Pulmonology and Hematology Center, Wroclaw, Poland
700    1_
$a Cokan, Andrej $u Department for Gynecological and Breast Oncology, UMC Maribor, Maribor, Slovenia
700    1_
$a Klát, Jaroslav $u Department of Obstetrics and Gynecology, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Ndukwe, Munachiso Iheme $u Department of Obstetrics and Gynecology, Faculty of Medicine, Hradec Kralove University Hospital, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Kryszpin, Marcin $u Lower Silesian Oncology, Pulmonology and Hematology Center, Wroclaw, Poland
700    1_
$a Poblocka, Renata $u Renata Poblocka, Gdynia, Poland
700    1_
$a Timošek, Eva $u Department for Gynecological and Breast Oncology, UMC Maribor, Maribor, Slovenia
700    1_
$a Romanová, Martina $u Department of Obstetrics and Gynecology, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Balcarová, Klára $u Department of Obstetrics and Gynecology, Faculty of Medicine, Hradec Kralove University Hospital, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Madry, Radoslaw $u Oncology Clinic, H. Swiecicki'S Hospital, Medical University of Poznan, Poznan, Poland
700    1_
$a Cibula, David $u First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic
773    0_
$w MED00004456 $t Supportive care in cancer $x 1433-7339 $g Roč. 33, č. 3 (2025), s. 202
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39969588 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134820 $b ABA008
999    __
$a ok $b bmc $g 2311316 $s 1246932
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 33 $c 3 $d 202 $e 20250219 $i 1433-7339 $m Supportive care in cancer $n Support Care Cancer $x MED00004456
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace